"Acquiring the US rights to PROVIGIL and NUVIGIL marks a strategic milestone for Apotex and a significant initial step in growing our US specialty business, building upon the recent achievement of ...

Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma. Design: Multicentre ...

TORONTO, Jan. 9, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced that its affiliate Nuvo Pharmaceuticals (Ireland) DAC has acquired ...